Birck, Marina G.
Lukusa, Luck
Choquette, Denis
Boire, Gilles
Maksymowych, Walter P.
Singh, Harminder
Afif, Waqqas
Bernatsky, Sasha
Article History
Received: 25 April 2024
Accepted: 6 September 2024
First Online: 27 September 2024
Declarations
:
: The study received approval from the McGill University Health Centre Research Ethics Board (MP-37–2019) and complies with the Declaration of Helsinki. The study used pan-Canadian claims and formulary administrative health data from the Canadian Institute for Health Information (CIHI). CIHI is a secondary data collector of health information providing researchers with third-party access to de-identified record-level data. No human participants were directly involved as the data disclosed to the authors was de-identified record-level data; therefore, obtaining individual consent is unnecessary.
: Not applicable.
: MGB, LL, and SB declare that they have no competing interests.DC created Rhumadata, which is supported through grants and research contracts from Amgen, AbbVie, CIHR, Novartis, Pfizer, Fresenius Kabi, Eli Lilly, Sandoz, and Tevapharm; he served as consultant or speaker for the same companies. GB: Biocon Biologics (Grant⁄Research Support);Eli Lilly (Advisor or Review Panel Member); Janssen (Speaker/Honoraria (includes speakers bureau, symposia, and expert witness); Organon (Advisor or Review Panel Member); Orimed Pharma (Advisor or Review Panel Member, Speaker/Honoraria (includes speakers bureau, symposia, and expert witness); Otsuka (Advisor or Review Panel Member); Pfizer (Advisor or Review Panel Member, Grant/Research Support); Sandoz (Advisor or Review Panel Member); Teva (Advisor or Review Panel Member); Viatris (Advisor or Review Panel Member, Speaker/Honoraria (includes speakers bureau, symposia, and expert witness). WPM Disclosures: Grant/research support from AbbVie, Novartis, Pfizer and UCB Pharma; consulting fees, speaking fees and/or honoraria fees from AbbVie, BMS, Celgene, Galapagos, Janssen, Eli-Lilly, Medscape, Novartis, Peervoice, Pfizer and UCB Pharma; is Chief Medical Officer of CARE Arthritis Limited. HS has been on advisory boards or consulted for Pendopharm, Amgen Canada, Abbvie Canada, Sandoz Canada, Takeda Canada, Innomar Strategies, Eli Lily Canada and Guardant Health, Inc; consulted for the Canadian Agency for Drugs and Technology in Health; has received research funding for an investigator-initiated study from Pfizer and holds shares of VasCon. WA reports having received speaker, advisory board member, and or clinical investigator for AbbVie, Amgen, BMS, Celltrion, Dynacare, Eli-Lilly, Janssen, Pfizer, Sandoz, Sanofi, Takeda.